



Discovery through partnership | Excellence through quality

StressXpress®

Cystatin C EIA Kit

Catalog# SKT-219 (96-Well Kit)

Colorimetric measurement of human cystatin C levels

TABLE OF CONTENTS

GENERAL INFORMATION	3	Materials Supplied
	4	Precautions
	4	Storage
	5	Materials Needed but Not Supplied
INTRODUCTION	6	Background
	7	Assay Overview
PRE-ASSAY PREPARATION	8	Sample Types
	8	Sample Preparation
	9	Reagent Preparation
ASSAY PROTOCOL	10	Assay Protocol
ANALYSIS	11	Calculation of Results
	11	Typical Data
	13	Validation Data
	15	Sample Values
	16	Cross Reactivity and Interferents
RESOURCES	17	References
	18	Warranty and Contact Information
	19	Plate Template
	20	Notes

GENERAL INFORMATION

Materials Supplied

Catalog Number	Reagent	Quantity	Description
SKC-219A	Clear Coated 96 Well Plate	One Plate	Clear plastic microplate with break-apart strips coated with mouse anti-human Cystatin C.
SKC-219B	Cystatin C Standard	60 μ L	A stock solution of native human Cystatin C at 400 ng/mL.
SKC-219C	StressXpress [®] Cystatin C Conjugate	5 mL	A monoclonal antibody to Cystatin C labeled with peroxidase.
SKC-219D	Assay Buffer Concentrate	28 mL	A 5X concentrate that should be diluted with deionized or distilled water.
SKC-219E	Wash Buffer Concentrate	30 mL	A 20X concentrate that should be diluted with deionized or distilled water.
SKC-219F	TMB Substrate	5 mL	-
SKC-219G	Stop Solution	5 mL	A 1N hydrochloric acid solution. Caustic.
SKC-219H	Plate Sealer	1 each	-

If any of the items listed above are damaged or missing, please contact our Customer Service department at (250) 294-9065. We cannot accept any returns without prior authorization.



WARNING: Not for human or animal disease diagnosis or therapeutic drug use.

Precautions

As with all such products, this kit should only be used by qualified personnel who have had laboratory safety instruction. The complete booklet should be read and understood before attempting to use the product.

The antibody coated plate needs to be stored desiccated. The silica gel pack included in the foil ziploc bag will keep the plate dry. The silica gel pack will turn from blue to pink if the ziploc has not been closed properly.

The Cystatin C Standard is purified from a human source and as such, should be treated as potentially hazardous. Proper safety procedures must be followed.

This kit utilizes a peroxidase-based readout system. Buffers, including other manufacturers Wash Buffers, containing sodium azide will inhibit color production from the enzyme. Make sure all buffers used for samples are azide free. Ensure that any plate washing system is rinsed well with deionized water prior to using the supplied Wash Buffer as prepared on page 9.

The Stop Solution is acid. The solution should not come in contact with skin or eyes. Take appropriate precautions when handling this reagent.

Storage

All components of this kit should be stored at 4 °C until the expiration date of the kit.

Materials Needed But Not Supplied

- Distilled or deionized water.
- A microplate washer.
- Colorimetric 96 well microplate reader capable of reading optical density at 450 nm, preferably with correction between 570 and 590 nm.
- Software for converting raw relative optical density readings from the plate reader and carrying out four parameter logistic curve (4PLC) fitting. Contact your plate reader manufacturer for details.

Please read this booklet completely prior to using the product. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Background

Cystatin C is a non-glycosylated protein of low molecular weight (13kDa) in the cystatin superfamily. Cystatin C is produced at a constant rate in all nucleated cells, secreted from cells and thus found in detectable amounts in most body fluids^{1,2}. Cystatin C belongs to the cysteine proteinase inhibitor group and is associated with several pathological conditions. Imbalance between Cystatin C and cysteine proteinases is associated with diseases such as inflammation, renal failure, cancer, Alzheimer's disease, multiple sclerosis and hereditary Cystatin C amyloid angiopathy^{1,3,4}. Increased levels have been found in autoimmune diseases, with colorectal tumors and metastases, patients with inflammation and in patients on dialysis^{5,6,7}. Cystatin C is removed from blood plasma by glomerular filtration in the kidneys. It is reabsorbed by the proximal tubular cells and degraded. There is a linear relationship between the reciprocal Cystatin C concentration in plasma and the glomerular filtration rate (GFR). Cystatin C is suggested to be a better marker for GFR than the ubiquitous serum creatinine marker as its serum concentration is not affected by other factors such as age, gender and body mass and Cystatin C has higher sensitivity to detect a reduced GFR than creatinine determination^{2,5}. Low levels of Cystatin C are found with the breakdown of the elastic laminae and atherosclerosis and abdominal aortic aneurysm⁸. There is evident association of Cystatin C levels with the incidence of myocardial infarction, coronary death and angina pectoris, presenting a risk factor for secondary cardiovascular events⁹.

Assay Overview

The Cystatin C StressXpress® EIA kit is designed to quantitatively measure human Cystatin C present in biological samples and tissue culture media. Please read the complete kit booklet before performing this assay. A human Cystatin C standard is provided to generate a standard curve for the assay and all samples should be read off the standard curve. Standards or diluted samples are pipetted into a clear microtiter plate coated with a monoclonal antibody to capture the Cystatin C present. After a 60 minute incubation, the plate is washed and a peroxidase conjugated Cystatin C monoclonal antibody is added. The plate is again incubated for 30 minutes and washed. Substrate is then added to the plate, which reacts with the bound Cystatin C Antibody Conjugate. After a third incubation, the reaction is stopped and the intensity of the generated color is detected in a microtiter plate reader capable of measuring 450 nm wavelength. The concentration of the Cystatin C in the sample is calculated, after making suitable correction for dilution, using software available with most plate readers.

PRE-ASSAY PREPARATION

Sample Types

Sample Types Validated:

Serum, EDTA and Heparin Plasma, Urine and Tissue Culture Media

This assay has been validated for human serum, EDTA and heparin plasma, urine and tissue culture media (TCM) samples only. Samples containing visible particulate should be centrifuged prior to using.

This assay has been shown to detect Cystatin C from human samples only.

Sample Preparation

Serum and plasma samples must be diluted $\geq 1:50$ with the provided Assay Buffer prior to running in the kit. A dilution of $\geq 1:225$ is recommended to detect most samples within the standard curve range. Disease state samples, such as those from tubular kidney disease, may require further dilutions up to 1:500 or greater. It is up to the end user to determine the appropriate dilution for their samples.

Urine samples must be diluted $\geq 1:4$ with the provided Assay Buffer prior to running in the kit.

TCM samples should be diluted in TCM and read off a standard curve generated in the same TCM.

Any samples with Cystatin C concentrations outside the standard curve range should be diluted further with Assay Buffer or TCM, as appropriate, to obtain readings within the standard curve.

Use all samples within 2 hours of dilution.

Reagent Preparation

Allow the kit reagents to come to room temperature for 30 minutes. We recommend that all standards and samples be run in duplicate to allow the end user to accurately determine Cystatin C concentrations. Ensure that all samples have reached room temperature and have been diluted as appropriate prior to running them in the kit.

Assay Buffer

Dilute Assay Buffer Concentrate 1:5 by adding one part of the concentrate to four parts of deionized water. Once diluted this is stable at 4°C for 3 months.


Wash Buffer

Dilute Wash Buffer Concentrate 1:20 by adding one part of the concentrate to nineteen parts of deionized water. Once diluted this is stable at room temperature for 3 months.

Standard Preparation

Label seven glass test tubes as #1 through #7. Briefly spin vial of standard in a microcentrifuge to ensure contents are at bottom of vial. Pipet 585 μL of Assay Buffer into tube #1 and 250 μL into tubes #2 to #7. Carefully add 15 μL of the Cystatin C stock solution to tube #1 and vortex completely. Take 250 μL of the Cystatin C solution in tube #1 and add it to tube #2 and vortex completely. Repeat the serial dilutions for tubes #3 through #7. The concentration of Cystatin C in tubes #1 through #7 will be 10, 5, 2.5, 1.25, 0.625, 0.313 and 0.156 ng/mL.

Use all Standards within 2 hours of preparation.



	Standard 1	Standard 2	Standard 3	Standard 4	Standard 5	Standard 6	Standard 7
Assay Buffer Volume (μL)	585	250	250	250	250	250	250
Addition	Stock	Standard 1	Standard 2	Standard 3	Standard 4	Standard 5	Standard 6
Volume of Addition (μL)	15	250	250	250	250	250	250
Final Concentration (ng/mL)	10	5	2.5	1.25	0.625	0.313	0.156

Assay Protocol

1. Use the plate layout sheet on page 21 of the booklet to aid in proper sample and standard identification. Determine the number of wells to be used and return unused wells to foil pouch with desiccant. Seal the ziploc plate bag and store at 4°C.
2. Pipet 50 µL of samples or standards into wells in the plate. Pipet 50 µL of Assay Buffer into the zero standard wells.
3. Incubate at room temperature for 60 minutes. Aspirate the plate and wash each well 4 times with 300 µL wash buffer. Tap the plate dry on clean absorbent towels.
4. Add 50 µL of the StressXpress® Cystatin C Conjugate to each well, using a repeater pipet.
5. Incubate at room temperature for 30 minutes.
6. Aspirate the plate and wash each well 4 times with 300 µL wash buffer. Tap the plate dry on clean absorbent towels.
7. Add 50 µL of the TMB Substrate to each well, using a repeater pipet.
8. Incubate the plate at room temperature for 30 minutes.
9. Add 50 µL of the Stop Solution to each well, using a repeater pipet.
10. Read the optical density generated from each well in a plate reader capable of reading at 450 nm.
11. Use the plate reader's built-in 4PLC software capabilities to calculate Cystatin C concentration for each sample.

ANALYSIS

Calculation of Results

Average the duplicate OD readings for each standard and sample. Create a standard curve by reducing the data using computer software capable of generating a four-parameter logistic curve (4PLC) fit. The sample concentrations should be multiplied by the dilution factor to obtain neat sample values.


Typical Data

Sample	Mean OD	Human Cystatin C Concentration (ng/mL)
Standard 1	1.595	10
Standard 2	0.810	5
Standard 3	0.399	2.5
Standard 4	0.221	1.25
Standard 5	0.129	0.625
Standard 6	0.082	0.313
Standard 7	0.061	0.156
B0	0.042	0
Sample 1	0.636	3.76
Sample 2	0.094	0.40

Always run your own standard curve for calculation of results.

Do not use this data.

Typical Standard Curves



Validation Data

Sensitivity and Limit of Detection

Sensitivity was calculated by comparing the OD's for twenty wells run for each of the zero and standard #7. The detection limit was determined at two (2) standard deviations from the zero along the standard curve.

Sensitivity was determined as 0.058 ng/mL. This is equivalent to less than 3 pg/well.

The Limit of Detection for the assay was determined in a similar manner by comparing the OD's for twenty replicates for each of the zero standard and a low concentration human serum sample.


Limit of Detection was determined as 0.171 ng/mL, equivalent to less than 9 pg/well.

Linearity


Serum linearity was determined by taking two human serum samples diluted 1:100, one with a low diluted Cystatin C level of 4.94 ng/mL and one with a higher diluted level of 12.31 ng/mL and mixing them in the ratios given below. Urine linearity samples were diluted 1:16. One sample with a value of 1.64 ng/mL was mixed in the ratios below with a sample of 3.72 ng/mL. The diluted serum and urine samples were mixed 4:1, 3:2, 2:3 and 1:4 and run in the assay. The measured concentrations were compared to the values previously determined.

High Sample	Low sample	Expected Concentration (ng/mL)		Observed Concentration (ng/mL)		% Recovery	
		Serum	Urine	Serum	Urine	Serum	Urine
80%	20%	10.84	3.30	11.44	3.57	105.6	108.1
60%	40%	9.36	2.89	9.15	2.90	97.7	100.4
40%	60%	7.89	2.47	7.77	2.42	98.5	97.9
20%	80%	6.41	2.06	5.80	1.82	90.4	88.5
Mean Recovery						98.1%	98.7%

Serum Linearity



Urine Linearity



Intra Assay Precision - DATA IN PROCESS

Four human samples were diluted with Assay Buffer and run in replicates of 20 in an assay. The mean and precision of the calculated Cystatin C concentrations were:

Sample	Cystatin C Concentration (ng/mL)	%CV
1	7.72	9.1
2	5.08	10.3
3	4.42	7.6
4	0.88	10.3

Inter Assay Precision

Four human samples were diluted with Assay Buffer and run in duplicates in ten assays run over multiple days by three operators. The mean and precision of the calculated Cystatin C concentrations were:

Sample	Cystatin C Concentration (ng/mL)	%CV
1	7.79	8.4
2	5.48	10.2
3	4.97	11.1
4	1.04	12.4

Sample Values

Thirteen random human serum samples were tested in the assay. Values ranged from 532.0 to 905.6 ng/mL with an average of 675 ng/mL. The normal reference range for serum Cystatin C is 590-910 ng/mL¹⁰. An abnormal serum sample read at 1,384 ng/mL.

Cross Reactivity and Interferents

A serum sample was spiked with varying concentrations of bilirubin, diluted 1:50 in Assay Buffer and tested in the assay. Bilirubin levels in normal serum are between 0.2 and 1.0 mg/dL¹¹. At 10 times the highest concentration normally seen in human samples there was a 14% decrease in measured Cystatin C concentration.

A serum sample was spiked with varying concentrations of hemoglobin in the form of RBCs, diluted 1:100 in Assay Buffer and tested in the assay. No significant change to the measured Cystatin C level was observed.

A serum sample was spiked with varying concentrations of lipids, diluted 1:50 in Assay Buffer and tested in the assay. No significant change to the measured Cystatin C level was observed with the addition of high, medium and low levels of lipids.

Dog, monkey, rat and mouse serum samples were serially diluted in the Assay Buffer and tested in the assay. No Cystatin C was detected.

This kit should not be used for non-human samples.

RESOURCES

References

1. Pergande M. and Jung K. “Sandwich Enzyme Immunoassay of Cystatin C in Serum with Commercially Available Antibodies.” *Clin Chem.* 1993 39(9):1885-90.
2. Newman D, et al. “Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine.” *Kidney Int'l.* 1995 Jan;47(1):312-8.
3. Levy E. “Cystatin C: a potential target for Alzheimer’s treatment.” *Expert Rev. Neurotherapeutics* 2008 May;8(5):687-9.
4. Nakashima I, et al. “Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis.” *Ann Neurol.* 2007 Aug;62(2):197-200.
5. Uchida K. and Gotoh, A. “Measurement of cystatin C and creatinine in urine.” *Clin Chim Acta.* 2002 Sep;323:121-8.
6. Pucci L, et al. “Cystatin C and Estimates of Renal Function: Searching for a Better Measure of Kidney Function in Diabetic Patients.” *Clin Chem.* 2007 Mar;53(3):480-8.
7. Stabuc B, et al. “Improved Prediction of Decreased Creatinine Clearance by Serum Cystatin C: Use in Cancer Patients before and during Chemotherapy.” *Clin Chem.* 2000 Feb;46(2):193-7.
8. Shlipak M, et al. “Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons.” *NEJM* 2005 May;352(20):2049-60.
9. Koenig W, et al. “Plasma Concentrations of Cystatin C in Patients with Coronary Heart Disease and Risk for Secondary Cardiovascular Events: More than Simply a Marker of Glomerular Filtration Rate.” *Clin Chem.* 2005 Feb;51(2):321-7.
10. “82994 Clinical: Cystatin C, Serum.” Mayo Medical Laboratories: Reference Laboratory services for hospitals worldwide. 25 June 2009 <http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/82994>.
11. Tietz, N.W., in “Textbook of Clinical Chemistry”, WB Sanders, 1986.

Warranty and Limitation of Remedy

StressMarq Biosciences Inc. makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. StressMarq **warrants only** to the original customer that the material will meet our specifications at the time of delivery. StressMarq will carry out its delivery obligations with due care and skill. Thus, in no event will StressMarq have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if StressMarq is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of StressMarq, its directors or its employees.

Buyer's **exclusive remedy** and StressMarq's sole liability hereunder shall be limited to a refund of the purchase price, or at StressMarq's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to StressMarq within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Refund Policy located on our website and in our catalog.

Contact Information

Phone:	250-294-9065
Fax:	250-294-9025
E-Mail:	techsupport@stressmarq.com
Hours:	M-F 9:00 AM to 5:00 PM PST

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

1												
2												
3												
4												
5												
6												
7												
8												
9												
10												
11												
12												
	A	B	C	D	E	F	G	H				

NOTES

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from StressMarq Biosciences Inc. ©08/28/2010, StressMarq Biosciences Inc., Victoria, BC Canada, All rights reserved. Printed in Canada.